2. Academic Validation
  3. N-Terminal Stabilization of Radiolabeled Neurotensin Analogues for Improved Tumor Uptake

N-Terminal Stabilization of Radiolabeled Neurotensin Analogues for Improved Tumor Uptake

  • J Med Chem. 2025 Apr 10;68(7):7280-7290. doi: 10.1021/acs.jmedchem.4c02844.
Sacha Bodin 1 2,  Tyrillshall S T Damiana 3,  Santo Previti 4,  Laure Balasse 5 6,  Lina Ali 2,  Emmanuelle Rémond 4,  Vincent Nail 5 6,  Frédéric Lamare 1 2,  Elif Hindié 1 2 7,  Benjamin Guillet 5 6,  Delphine Vimont 2,  Simone U Dalm 3,  Florine Cavelier 4,  Clément Morgat 1 2
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine & Radiopharmacy, CHU de Bordeaux, F-33000 Bordeaux, France.
  • 2 CNRS, EPHE, INCIA, UMR 5287, University of Bordeaux, F-33000 Bordeaux, France.
  • 3 Department of Radiology & Nuclear Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.
  • 4 Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université de Montpellier, ENSCM, 1919 route de Mende, 34293 Montpellier Cedex 5, France.
  • 5 INSERM, Institut National de la Recherche Agronomique, Centre de Recherche en Cardiovasculaire et Nutrition, Aix-Marseille University, 13385 Marseille, France.
  • 6 Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille University, 13005 Marseille, France.
  • 7 Institut Universitaire de France, IUF, F-75000 Paris, France.
PMID: 40111113 DOI: 10.1021/acs.jmedchem.4c02844
Abstract

Peptide-based radiopharmaceuticals targeting neurotensin-receptor-1 (NTS1) are mainly stabilized using chemical modifications at the NT[8-13] sequence, thus increasing the stability and the uptake of the corresponding radionuclide-macrocycle-linker-bioconjugate. We postulate that the introduction of the linker at the N-term part induces additional cleavage sites that can be further stabilized to achieve a prolonged uptake. Double (JMV 7259 and JMV 7222) and triple-stabilized neurotensin analogues (JMV 7258 and JMV 7490) were synthesized, radiolabeled, and evaluated on HT-29 cells (NTS1+). Nanomolar NTS1-affinity and high internalization rates were observed for all of the radiopharmaceuticals. Efflux was lower for radiolabeled JMV 7490. Consequently, [111In]In-JMV 7490 showed uptake of 5.86 ± 0.86 and 3.65 ± 0.29% ID/g of tissue in HT-29 xenografts at 1 and 4 h, respectively. We have successfully shown that high and persistent uptake of NTS1-positive tumor cells is achievable by stabilization of the N-term part. Efflux also appears to be a critical parameter for the successful targeting of NTS1 using radiopharmaceuticals.

Figures
Products